Why Did Buffett Sell the S&P 500?
Warren Buffett has always been an advocate of investing in…
Sell
1
THNR Quote, Financials, Valuation and Earnings
Last price:
$21.50
Seasonality move
:
--
Day range:
$21.55 - $21.59
52-week range:
$21.55 - $28.19
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
217
Avg. volume:
906
1-year change:
--
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
-- | -- | -- | -- | -- |
|
CNCR
Range Cancer Therapeutics ETF
|
-- | -- | -- | -- | -- |
|
EKG
First Trust Nasdaq Lux Digi Health Solutions ETF
|
-- | -- | -- | -- | -- |
|
GDOC
Goldman Sachs Future Health Care Equity ETF
|
-- | -- | -- | -- | -- |
|
OZEM
Roundhill GLP-1 & Weight Loss ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
$21.55 | -- | -- | -- | $0.22 | 0% | -- |
|
CNCR
Range Cancer Therapeutics ETF
|
$9.87 | -- | -- | -- | $0.00 | 0% | -- |
|
EKG
First Trust Nasdaq Lux Digi Health Solutions ETF
|
$15.68 | -- | -- | -- | $0.00 | 0% | -- |
|
GDOC
Goldman Sachs Future Health Care Equity ETF
|
$32.23 | -- | -- | -- | $0.01 | 0.02% | -- |
|
OZEM
Roundhill GLP-1 & Weight Loss ETF
|
$23.56 | -- | -- | -- | $0.05 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
-- | 0.000 | -- | -- |
|
CNCR
Range Cancer Therapeutics ETF
|
-- | 1.328 | -- | -- |
|
EKG
First Trust Nasdaq Lux Digi Health Solutions ETF
|
-- | 1.696 | -- | -- |
|
GDOC
Goldman Sachs Future Health Care Equity ETF
|
-- | 1.161 | -- | -- |
|
OZEM
Roundhill GLP-1 & Weight Loss ETF
|
-- | 0.000 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
THNR
Amplify Weight Loss Drug & Treatment ETF
|
-- | -- | -- | -- | -- | -- |
|
CNCR
Range Cancer Therapeutics ETF
|
-- | -- | -- | -- | -- | -- |
|
EKG
First Trust Nasdaq Lux Digi Health Solutions ETF
|
-- | -- | -- | -- | -- | -- |
|
GDOC
Goldman Sachs Future Health Care Equity ETF
|
-- | -- | -- | -- | -- | -- |
|
OZEM
Roundhill GLP-1 & Weight Loss ETF
|
-- | -- | -- | -- | -- | -- |
Amplify Weight Loss Drug & Treatment ETF vs. Competitors
-
Which has Higher Returns THNR or CNCR?
Range Cancer Therapeutics ETF has a net margin of -- compared to Amplify Weight Loss Drug & Treatment ETF's net margin of --. Amplify Weight Loss Drug & Treatment ETF's return on equity of -- beat Range Cancer Therapeutics ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- CNCRRange Cancer Therapeutics ETF-- -- -- -
What do Analysts Say About THNR or CNCR?
Amplify Weight Loss Drug & Treatment ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Range Cancer Therapeutics ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Amplify Weight Loss Drug & Treatment ETF has higher upside potential than Range Cancer Therapeutics ETF, analysts believe Amplify Weight Loss Drug & Treatment ETF is more attractive than Range Cancer Therapeutics ETF.
Company Buy Ratings Hold Ratings Sell Ratings THNRAmplify Weight Loss Drug & Treatment ETF0 0 0 CNCRRange Cancer Therapeutics ETF0 0 0 -
Is THNR or CNCR More Risky?
Amplify Weight Loss Drug & Treatment ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Range Cancer Therapeutics ETF has a beta of 1.003, suggesting its more volatile than the S&P 500 by 0.282%.
-
Which is a Better Dividend Stock THNR or CNCR?
Amplify Weight Loss Drug & Treatment ETF has a quarterly dividend of $0.22 per share corresponding to a yield of 0%. Range Cancer Therapeutics ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amplify Weight Loss Drug & Treatment ETF pays -- of its earnings as a dividend. Range Cancer Therapeutics ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios THNR or CNCR?
Amplify Weight Loss Drug & Treatment ETF quarterly revenues are --, which are smaller than Range Cancer Therapeutics ETF quarterly revenues of --. Amplify Weight Loss Drug & Treatment ETF's net income of -- is lower than Range Cancer Therapeutics ETF's net income of --. Notably, Amplify Weight Loss Drug & Treatment ETF's price-to-earnings ratio is -- while Range Cancer Therapeutics ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amplify Weight Loss Drug & Treatment ETF is -- versus -- for Range Cancer Therapeutics ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- -- CNCRRange Cancer Therapeutics ETF-- -- -- --
-
Which has Higher Returns THNR or EKG?
First Trust Nasdaq Lux Digi Health Solutions ETF has a net margin of -- compared to Amplify Weight Loss Drug & Treatment ETF's net margin of --. Amplify Weight Loss Drug & Treatment ETF's return on equity of -- beat First Trust Nasdaq Lux Digi Health Solutions ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- EKGFirst Trust Nasdaq Lux Digi Health Solutions ETF-- -- -- -
What do Analysts Say About THNR or EKG?
Amplify Weight Loss Drug & Treatment ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand First Trust Nasdaq Lux Digi Health Solutions ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Amplify Weight Loss Drug & Treatment ETF has higher upside potential than First Trust Nasdaq Lux Digi Health Solutions ETF, analysts believe Amplify Weight Loss Drug & Treatment ETF is more attractive than First Trust Nasdaq Lux Digi Health Solutions ETF.
Company Buy Ratings Hold Ratings Sell Ratings THNRAmplify Weight Loss Drug & Treatment ETF0 0 0 EKGFirst Trust Nasdaq Lux Digi Health Solutions ETF0 0 0 -
Is THNR or EKG More Risky?
Amplify Weight Loss Drug & Treatment ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison First Trust Nasdaq Lux Digi Health Solutions ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock THNR or EKG?
Amplify Weight Loss Drug & Treatment ETF has a quarterly dividend of $0.22 per share corresponding to a yield of 0%. First Trust Nasdaq Lux Digi Health Solutions ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amplify Weight Loss Drug & Treatment ETF pays -- of its earnings as a dividend. First Trust Nasdaq Lux Digi Health Solutions ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios THNR or EKG?
Amplify Weight Loss Drug & Treatment ETF quarterly revenues are --, which are smaller than First Trust Nasdaq Lux Digi Health Solutions ETF quarterly revenues of --. Amplify Weight Loss Drug & Treatment ETF's net income of -- is lower than First Trust Nasdaq Lux Digi Health Solutions ETF's net income of --. Notably, Amplify Weight Loss Drug & Treatment ETF's price-to-earnings ratio is -- while First Trust Nasdaq Lux Digi Health Solutions ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amplify Weight Loss Drug & Treatment ETF is -- versus -- for First Trust Nasdaq Lux Digi Health Solutions ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- -- EKGFirst Trust Nasdaq Lux Digi Health Solutions ETF-- -- -- --
-
Which has Higher Returns THNR or GDOC?
Goldman Sachs Future Health Care Equity ETF has a net margin of -- compared to Amplify Weight Loss Drug & Treatment ETF's net margin of --. Amplify Weight Loss Drug & Treatment ETF's return on equity of -- beat Goldman Sachs Future Health Care Equity ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- GDOCGoldman Sachs Future Health Care Equity ETF-- -- -- -
What do Analysts Say About THNR or GDOC?
Amplify Weight Loss Drug & Treatment ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Goldman Sachs Future Health Care Equity ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Amplify Weight Loss Drug & Treatment ETF has higher upside potential than Goldman Sachs Future Health Care Equity ETF, analysts believe Amplify Weight Loss Drug & Treatment ETF is more attractive than Goldman Sachs Future Health Care Equity ETF.
Company Buy Ratings Hold Ratings Sell Ratings THNRAmplify Weight Loss Drug & Treatment ETF0 0 0 GDOCGoldman Sachs Future Health Care Equity ETF0 0 0 -
Is THNR or GDOC More Risky?
Amplify Weight Loss Drug & Treatment ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Goldman Sachs Future Health Care Equity ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock THNR or GDOC?
Amplify Weight Loss Drug & Treatment ETF has a quarterly dividend of $0.22 per share corresponding to a yield of 0%. Goldman Sachs Future Health Care Equity ETF offers a yield of 0.02% to investors and pays a quarterly dividend of $0.01 per share. Amplify Weight Loss Drug & Treatment ETF pays -- of its earnings as a dividend. Goldman Sachs Future Health Care Equity ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios THNR or GDOC?
Amplify Weight Loss Drug & Treatment ETF quarterly revenues are --, which are smaller than Goldman Sachs Future Health Care Equity ETF quarterly revenues of --. Amplify Weight Loss Drug & Treatment ETF's net income of -- is lower than Goldman Sachs Future Health Care Equity ETF's net income of --. Notably, Amplify Weight Loss Drug & Treatment ETF's price-to-earnings ratio is -- while Goldman Sachs Future Health Care Equity ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amplify Weight Loss Drug & Treatment ETF is -- versus -- for Goldman Sachs Future Health Care Equity ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- -- GDOCGoldman Sachs Future Health Care Equity ETF-- -- -- --
-
Which has Higher Returns THNR or OZEM?
Roundhill GLP-1 & Weight Loss ETF has a net margin of -- compared to Amplify Weight Loss Drug & Treatment ETF's net margin of --. Amplify Weight Loss Drug & Treatment ETF's return on equity of -- beat Roundhill GLP-1 & Weight Loss ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- OZEMRoundhill GLP-1 & Weight Loss ETF-- -- -- -
What do Analysts Say About THNR or OZEM?
Amplify Weight Loss Drug & Treatment ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Roundhill GLP-1 & Weight Loss ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Amplify Weight Loss Drug & Treatment ETF has higher upside potential than Roundhill GLP-1 & Weight Loss ETF, analysts believe Amplify Weight Loss Drug & Treatment ETF is more attractive than Roundhill GLP-1 & Weight Loss ETF.
Company Buy Ratings Hold Ratings Sell Ratings THNRAmplify Weight Loss Drug & Treatment ETF0 0 0 OZEMRoundhill GLP-1 & Weight Loss ETF0 0 0 -
Is THNR or OZEM More Risky?
Amplify Weight Loss Drug & Treatment ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Roundhill GLP-1 & Weight Loss ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock THNR or OZEM?
Amplify Weight Loss Drug & Treatment ETF has a quarterly dividend of $0.22 per share corresponding to a yield of 0%. Roundhill GLP-1 & Weight Loss ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.05 per share. Amplify Weight Loss Drug & Treatment ETF pays -- of its earnings as a dividend. Roundhill GLP-1 & Weight Loss ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios THNR or OZEM?
Amplify Weight Loss Drug & Treatment ETF quarterly revenues are --, which are smaller than Roundhill GLP-1 & Weight Loss ETF quarterly revenues of --. Amplify Weight Loss Drug & Treatment ETF's net income of -- is lower than Roundhill GLP-1 & Weight Loss ETF's net income of --. Notably, Amplify Weight Loss Drug & Treatment ETF's price-to-earnings ratio is -- while Roundhill GLP-1 & Weight Loss ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amplify Weight Loss Drug & Treatment ETF is -- versus -- for Roundhill GLP-1 & Weight Loss ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income THNRAmplify Weight Loss Drug & Treatment ETF-- -- -- -- OZEMRoundhill GLP-1 & Weight Loss ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will SoundHound AI Stock Recover?
SoundHound AI (NASDAQ:SOUN) is a leading maker of artificial intelligence…
What Stocks Did Warren Buffett Just Buy?
In Q4 of last year, Warren Buffett added to or…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
41
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
78
AJINY alert for Mar 29
Ajinomoto [AJINY] is up 99.61% over the past day.
Buy
69
AGX alert for Mar 29
Argan [AGX] is up 19.83% over the past day.
Sell
24
AIR alert for Mar 29
AAR [AIR] is down 16.36% over the past day.
